Total Valuation
Gilead Sciences has a market cap or net worth of CHF151.00B. The enterprise value is CHF178.32K.
Market CapCHF151.00B
Enterprise ValueCHF178.32K
Share Statistics
Gilead Sciences has 1,239,955,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,239,955,200
Owned by Insiders0.08%
Owned by Institutions16.13%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is 20.32%.
Return on Equity (ROE)0.37
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)20.32%
Return on Capital Employed (ROCE)0.25
Revenue Per Employee1.73M
Profits Per Employee500.59K
Employee Count17,000
Asset Turnover0.50
Inventory Turnover3.51
Valuation Ratios
The current PE Ratio of Gilead Sciences is ―. Gilead Sciences’s PEG ratio is 0.01.
PE Ratio―
PS Ratio5.19
PB Ratio6.73
Price to Fair Value6.73
Price to FCF16.15
Price to Operating Cash Flow13.84
PEG Ratio0.01
Income Statement
In the last 12 months, Gilead Sciences had revenue of 29.44B and earned 8.51B in profits. Earnings per share was 6.84.
Revenue29.44B
Gross Profit23.21B
Operating Income11.70B
Pretax Income9.80B
Net Income8.51B
EBITDA13.58B
Earnings Per Share (EPS)6.84
Cash Flow
In the last 12 months, operating cash flow was 13.55B and capital expenditures -352.00M, giving a free cash flow of 13.20B billion.
Operating Cash Flow13.55B
Free Cash Flow13.20B
Free Cash Flow per Share10.64
Dividends & Yields
Gilead Sciences pays an annual dividend of CHF0.664, resulting in a dividend yield of 2.14%
Dividend Per ShareCHF0.664
Dividend Yield2.14%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.20
52-Week Price Change84.16%
50-Day Moving Average112.06
200-Day Moving Average98.37
Relative Strength Index (RSI)75.82
Average Volume (3m)0.00
Important Dates
Gilead Sciences upcoming earnings date is Oct 22, 2026, After Close (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
Gilead Sciences as a current ratio of 1.55, with Debt / Equity ratio of 221.90%
Current Ratio1.55
Quick Ratio1.40
Debt to Market Cap0.16
Net Debt to EBITDA1.28
Interest Coverage Ratio11.43
Taxes
In the past 12 months, Gilead Sciences has paid 1.29B in taxes.
Income Tax1.29B
Effective Tax Rate0.13
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 12.52, with an EV/FCF ratio of 17.98.
EV to Sales5.78
EV to EBITDA12.52
EV to Free Cash Flow17.98
EV to Operating Cash Flow16.97
Balance Sheet
Gilead Sciences has CHF3.18B in cash and marketable securities with CHF26.25B in debt, giving a net cash position of -CHF23.07B billion.
Cash & Marketable SecuritiesCHF3.18B
Total DebtCHF26.25B
Net Cash-CHF23.07B
Net Cash Per Share-CHF18.60
Tangible Book Value Per Share-CHF2.15
Margins
Gross margin is 79.59%, with operating margin of 39.74%, and net profit margin of 28.90%.
Gross Margin79.59%
Operating Margin39.74%
Pretax Margin33.27%
Net Profit Margin28.90%
EBITDA Margin46.12%
EBIT Margin36.75%
Analyst Forecast
The average price target for Gilead Sciences is CHF130.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF130.40
Price Target Upside9.78% Upside
Analyst ConsensusStrong Buy
Analyst Count21
Revenue Growth Forecast-2.93%
EPS Growth Forecast-146.39%